Skip to content

Stock-Based Comp at other companies

HRO
HarrowHROW
$3.84M-15.8%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$3.11M-0.3%
XER
Xeris Biopharma Holdings, Inc.XERS
$4.14M-6.8%
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
$10.19M+14.9%
Crinetics Pharmaceuticals logo
Crinetics PharmaceuticalsCRNX
$29.68M+44.9%
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
$6.26M+7.0%

Other financials

Income statement

See full
Revenue$24.3M+40.4%
Gross profit$14.7M+49.4%
Operating income$2.4M+614%
Net income$1.6M+199%
EPS (diluted)$0.05+183%

Balance sheet

See full
Cash & equivalents$19.7M+12.9%
Total debt$31.3M+3.7%
Total equity$30.6M+25.2%
Total assets$97.7M+16.3%

Cash flow

See full
Operating cash flow$7.4M+254%
CapEx$75.0K
Free cash flow$7.3M+251%

Valuation

See full
Market cap$953.8M+162%
Enterprise value$965.4M+156%
P/S11×+3.4×

Profitability

See full
Gross margin54.8%-3.7pp
Operating margin-15.1%
Net margin-9.5%-2.7pp
FCF margin17.1%

Returns & leverage

See full
Return on equity-34.2%+0.9pp
Debt / equity-0.2×
Current ratio1.2×-0.8×

Where this comes from

Reported directly by Eton Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: Eton Pharmaceuticals, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Eton Pharmaceuticals, Inc.'s stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Eton Pharmaceuticals, Inc.'s stock-based comp?
Eton Pharmaceuticals, Inc. (ETON) reported stock-based comp of $1.52M in Q1 2026.
How has Eton Pharmaceuticals, Inc.'s stock-based comp changed year-over-year?
Eton Pharmaceuticals, Inc.'s stock-based comp increased by 26.5% year-over-year, from $1.2M to $1.52M.
What is the long-term trend for Eton Pharmaceuticals, Inc.'s stock-based comp?
Over 4 years (2021 to 2025), Eton Pharmaceuticals, Inc.'s stock-based comp has grown at a 13.0% compound annual growth rate (CAGR), from $3.38M to $5.51M.
What does stock-based comp mean?
Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.